Claims for Patent: 9,775,844

Summary for Patent: 9,775,844

Title:	Heterocyclic compounds and uses thereof
Abstract:	Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
Inventor(s):	Kutok; Jeffery L. (Natick, MA), Winkler; David G. (Arlington, MA), Palombella; Vito J. (Needham, MA), Castro; Alfredo C. (Woburn, MA), Evans; Catherine A. (Somerville, MA), Janardanannair; Somarajannair (Woburn, MA), Lescarbeau; Andre (Somerville, MA), Liu; Tao (Wellesley, MA), Tremblay; Martin R. (Melrose, MA)
Assignee:	Infinity Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:	14/661,656
Patent Claims:	1. A method of treating a PI3K-gamma mediated disorder in a subject, comprising administering to the subject a therapeutically effective amount of a compound of the formula: ##STR01622## or a pharmaceutically acceptable salt thereof. 2. The method of claim 1, wherein the subject has a PI3K-gamma mediated disorder selected from cancer, an inflammatory disease, or an autoimmune disease. 3. The method of claim 2, wherein the disorder is cancer and the cancer is a solid tumor. 4. The method of claim 2, wherein the disorder is a cancer selected from one or more of: a cancer of the pulmonary system, a brain cancer, a cancer of the gastrointestinal tract, a skin cancer, a genitourinary cancer, head and neck cancer, a sarcoma, a carcinoma, and a neuroendocrine cancer. 5. The method of claim 1, wherein the subject is a human. 6. The method of claim 1, wherein the therapeutically effective amount of the compound is about 2 mg per day, about 1-3 mg per day, about 1-5 mg per day, about 1-10 mg per day, about 0.5-20 mg per day, about 0.1-50 mg per day, about 0.1-75 mg per day, about 0.1-100 mg per day, about 0.1-250 mg per day, about 0.1-500 mg per day, about 0.1-1000 mg per day, about 1-50 mg per day, about 1-75 mg per day, about 1-100 mg per day, about 1-250 mg per day, about 1-500 mg per day, about 1-1000 mg per day, about 10-50 mg per day, about 10-75 mg per day, about 10-100 mg per day, about 10-250 mg per day, about 10-500 mg per day, about 10-1000 mg per day, about 100-500 mg per day, or about 100-1000 mg per day. 7. The method of claim 1, wherein the therapeutically effective amount of the compound is about 0.029 mg/kg, about 0.014-0.14 mg/kg, about 0.02-0.04 mg/kg, about 0.01-0.05 mg/kg, about 0.01-0.1 mg/kg, or about 0.01-0.5 mg/kg. 8. The method of claim 1, wherein the compound is administered once every two days. 9. The method of claim 1, wherein the compound is administered once per day. 10. The method of claim 1, wherein the compound is administered twice per day. 11. The method of claim 1, wherein the compound is administered at a dose such that the level of the compound in the subject is higher than the compound's IC.sub.50 of PI3K-gamma inhibition during at least 70%, 80%, 90%, 95%, 97%, 98%, or 99% of 6 hours, 12 hours, 24 hours, or 48 hours immediately following the administration. 12. The method of claim 1, wherein the compound is administered at a dose such that the level of the compound in the subject is higher than the compound's IC.sub.90 of PI3K-gamma inhibition during at least 50%, 60%, 70%, 80%, 90%, 95%, 97%, 98%, or 99% of 6 hours, 12 hours, 24 hours, or 48 hours immediately following the administration. 13. The method of claim 1, wherein the compound is administered at a dose such that the level of the compound in the subject does not rise higher than the compound's IC.sub.20 or IC.sub.50 of PI3K-delta inhibition within 6 hours, 12 hours, 24 hours, or 48 hours immediately following the administration. 14. The method of claim 1, wherein the compound is administered at a dose such that it provides at least 50% inhibition of PI3K-gamma in the subject but less than 10% or 20% inhibition of PI3K-delta in the subject. 15. The method of claim 1, wherein the subject is a human and the compound has a half life of about 10-13 hours in the subject. 16. The method of claim 2, wherein the disorder is a cancer selected from one or more of: a pancreatic cancer, a lung cancer, a breast cancer, a prostate cancer, a testicular cancer, an esophageal cancer, a liver cancer, a gastric cancer, a colon cancer, a colorectal cancer, an ovarian cancer, a cervical cancer, a uterine cancer, an endometrial cancer, a bladder cancer, a kidney cancer, and a viral-induced cancer. 17. The method of claim 2, wherein the disorder is a cancer selected from one or more of: a medullobastoma, a basal cell carcinoma, a glioma, a hepatocellular cancer, a gastrointestinal stromal tumor (GIST), a melanoma, a neuroectodermal tumor, a soft-tissue sarcoma, fibrosarcoma, myxosarcoma, liposarcoma, a chondrosarcoma, an osteogenic sarcoma, a chordoma, an angiosarcoma, an endotheliosarcoma, a lymphangiosarcoma, a lymphangioendotheliosarcoma, a synovioma, a mesothelioma, a leiomyosarcoma, a bladder carcinoma, an epithelial carcinoma, a squamous cell carcinoma, an adenocarcinoma, a bronchogenic carcinoma, a renal cell carcinoma, a hepatoma, a bile duct carcinoma, a carcinoid tumor, diffuse type giant cell tumor, and glioblastoma. 18. The method of claim 3, wherein the solid tumor is melanoma, lung cancer, head and neck cancer, renal cell carcinoma, bladder cancer, breast cancer, colon cancer, or glioblastoma. 19. The method of claim 18, wherein the solid tumor is non-small cell lung cancer. 20. The method of claim 2, wherein the cancer is metastatic. 21. The method of claim 1, wherein the compound is administered at a dose of about 10, about 15, about 20, about 25, about 30, about 35, or about 40 mg once daily. 22. The method of claim 3, which further comprises administering to the subject a second therapeutic agent that is a P-gp substrate. 23. The method of claim 3, which further comprises administering a PI3K-delta inhibitor to the subject. 24. The method of claim 3, which further comprises administering an immunomodulator to the subject. 25. The method of claim 24, wherein the immunomodulator is a NKG2C ligand, a NKG2D ligand, a CTLA-4 inhibitor, a PD-1 inhibitor, a PDL-1 inhibitor, a LAG3 inhibitor, a TIM-3 inhibitor, a BTLA inhibitor, a VISTA inhibitor, a TIGIT inhibitor, a HDAC inhibitor, a proteasome inhibitor, an IDO inhibitor, a CSF1 inhibitor, a CCL2 antibdoy, an ARG1 inhibitor, a CD28 agonist, an ICOS agonist, a CD137 agonist, an OX40 agonist, a GITR agonist, a CD27 agonist, a CD30 agonist, a HVEM agonist, a CD28 agonist, a TLF ligand, GMCSF, a CD40 agonist, or a B7-H3 antibody. 26. The method of claim 24, wherein the immunomodulator is a PDL-1 inhibitor or an anti-PDL-1 antibody. 27. The method of claim 26, wherein the PD-L1 inhibitor or the anti-PDL-1 antibody is YW243.55.S70, MDPL3280A, MSB0010718C, MDX-1105, or MEDI-4736. 28. The method of claim 24, wherein the immunomodulator is a PD-1 inhibitor or an anti-PD-1 antibody. 29. The method of claim 28, wherein the PD-1 inhibitor or the anti-PD-1 antibody is nivolumab, pembrolizumab, pidilizumab, AMP-244, or AMP-514. 30. The method of claim 29, wherein the PD-1 inhibitor or the anti-PD-1 antibody is nivolumab. 31. The method of claim 29, wherein the PD-1 inhibitor or the anti-PD-1 antibody is pembrolizumab. 32. The method of claim 24, wherein the immunomodulator is a CTLA-4 inhibitor or an anti-CTLA4 antibody. 33. The method of claim 32, wherein the CTLA-4 inhibitor or the anti-CTLA4 antibody is tremelimumab or ipilimumab. 34. The method of claim 24, wherein the immunomodulator is a combination of a PD-1 inhibitor or an anti-PD-1 antibody and a CTLA-4 inhibitor or an anti-CTLA-4 antibody. 35. The method of claim 34, wherein the PD-1 inhibitor or the anti-PD-1 antibody is selected from the group consisting of nivolumab, pembrolizumab, pidilizumab, AMP-244, and AMP-514, and the CTLA-4 inhibitor or the anti-CTLA-4 antibody is selected from the group consisting of tremelimumab and ipilimumab. 36. The method of claim 35, wherein the PD-1 inhibitor or the anti-PD-1 antibody is nivolumab. 37. The method of claim 35, wherein the PD-1 inhibitor or the anti-PD-1 antibody is pembrolizumab. 38. The method of claim 24, wherein the immunomodulator is a combination of a PD-1 inhibitor or an anti-PD-1 antibody, a PDL-1 inhibitor or an anti-PDL-1 antibody, and a CTLA-4 inhibitor or an anti-CTLA-4 antibody. 39. The method of claim 24, wherein the immunomodulator is a combination of an antibody or fragment thereof, an inhibitory nucleic acid, a soluble ligand, or a fusion of PD-1 with a Fc region of an immunoglobulin; an antibody or fragment thereof, an inhibitory nucleic acid, a soluble ligand, or a fusion of PD-L1 with a Fc region of an immunoglobulin; and an antibody or fragment thereof, an inhibitory nucleic acid, a soluble ligand, or a fusion of a CTLA-4 ligand with a Fc region of an immunoglobulin. 40. The method of claim 24, wherein the immunomodulator is a costimulatory ligand, a MCSF/CSF-1R inhibitor, an immunostimulant, a CXCR4/CXCL12 inhibitor, a CCL2 inhibitor, or a CCR2 inhibitor. 41. The method of claim 40, wherein the immunostimulant is GMCSF. 42. The method of claim 24, wherein the immunomodulator is cyclophosphamide, docetaxel, paclitaxel, 5-FU, or temozolomide. 43. The method of claim 3, which further comprises administering gemcitabine to the subject. 44. The method of claim 3, wherein the compound is administered in combination with a radiation therapy or a chemotherapy. 45. The method of claim 44, wherein the compound is administered after the administration of the radiation therapy or the chemotherapy. 46. The method of claim 6, wherein the therapeutically effective amount of the compound is about 1-100 mg per day. 47. The method of claim 24, wherein the immunomodulator is an IDO inhibitor. 48. The method of claim 47, wherein the IDO inhibitor is indoximod, NLG919, INCB024360, F001287, norharmane, rosmarinic acid, or alpha-methyl-tryptophan.

Details for Patent 9,775,844

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bristol-myers Squibb Company	YERVOY	ipilimumab	Injection	125377	03/25/2011		2034-03-19
Merck Sharp & Dohme Corp.	KEYTRUDA	pembrolizumab	For Injection	125514	09/04/2014		2034-03-19
Merck Sharp & Dohme Corp.	KEYTRUDA	pembrolizumab	Injection	125514	01/15/2015		2034-03-19
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	12/22/2014		2034-03-19
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	10/04/2017		2034-03-19
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	08/27/2021		2034-03-19